Where is Biolevate headquartered?

Biolevate is headquartered in Paris, France. The company has a team of 11-50 people.

What does Biolevate do?

Biolevate operates in the AI in Healthcare sector. Paris-based life sciences AI company building an evidence-grounded, enterprise agentic platform that automates scientific and regulatory workflows for pharma and regulated industries. Evidence-grade, auditable agentic AI that turns scientific and regulatory knowledge into governed workflows, enabling life sciences organizations to deploy AI safely in regulated environments with human oversight.

When was Biolevate founded?

Biolevate was founded in 2023. It is based in Paris, France.

Who is the CEO of Biolevate?

Joël Belafa is the CEO of Biolevate. The company was founded in 2023.

Where is Biolevate located?

Biolevate is headquartered in Paris, France.

What funding stage is Biolevate at?

Biolevate is currently at the Growth Stage stage.

How many employees does Biolevate have?

Biolevate has approximately 11-50 employees.

Biolevate

Category: AI in Healthcare

Paris-based life sciences AI company building an evidence-grounded, enterprise agentic platform that automates scientific and regulatory workflows for pharma and regulated industries. Biolevate was founded in 2023. The company is led by Joël Belafa. Based in Paris, France. Team size: 11-50. Total funding raised: $39.4M. Latest round: Series A. Key investors include RAISE France, Orange Ventures, MSD Global Health Innovation Fund (MGHIF), Station F, EQT Ventures, Bpifrance, Mehdi Ghissassi (angel).

Founded: 2023
Headquarters: Paris, France
Team size: 11-50
Total funding: $39.4M

Value proposition

Evidence-grade, auditable agentic AI that turns scientific and regulatory knowledge into governed workflows, enabling life sciences organizations to deploy AI safely in regulated environments with human oversight.

Products and solutions

Evidence-grade agentic AI platform (formerly ELISE) covering: clinical protocol co-authoring, CSR co-authoring, evidence gap mapping & roadmap planning, governed medical answers for MSLs, regulatory change monitoring & impact mapping, PSUR change mapping & co-authoring, safety signal surveillance & triage, evidence-based competitive intelligence, batch records QC, quality & manufacturing protocol co-authoring, HTA decision intelligence, CTD generation.

Unique value

Hyperspecialized enterprise agentic platform whose outputs stay grounded in source evidence at every stage — unlike general-purpose AI — capable of running up to 100,000 agents concurrently, purpose-built for regulated life-sciences workflows.

Target customer

Enterprise life sciences organizations: pharmaceutical, medical device, cosmetics and nutrition companies across research, clinical, regulatory, market access, lifecycle and manufacturing functions.

Industries served

Life sciences / pharmaceuticals, medical devices, cosmetics, nutrition, regulatory affairs, pharmacovigilance, clinical development, market access (HTA)

Technology advantage

Evidence-grounded agentic architecture with full run-record auditability and human-in-the-loop governance; scales to 100,000 concurrent agents; frontier AI research applied to regulated life-sciences knowledge (scientific documents, biological knowledge graphs); NVIDIA BioNeMo Agent Toolkit integration for AI-native drug discovery; 7 patent applications drafted across therapeutic areas (2 filed in Europe).

How they differentiate

Unlike general-purpose LLM tools and broader life-sciences data platforms, Biolevate is hyperspecialized for regulated evidence-grade workflows — every output is source-grounded and auditable, with human-in-the-loop governance and massive agent concurrency (100k agents), targeting the route-to-market bottleneck rather than drug discovery alone.

Main competitors

Owkin, Novotech, Dotmatics

Key partnerships

Sanofi, NVIDIA (BioNeMo Agent Toolkit), Microsoft (Pegasus Program for enterprise GTM), Station F, regulators

Notable customers

Sanofi, more than a dozen enterprise customers in production (undisclosed)

Major milestones

Founded 2023 in Paris, €6M seed led by EQT Ventures (Nov 2024), selected for Station F Future40 2024, joined Microsoft Pegasus Program, NVIDIA BioNeMo Agent Toolkit collaboration, €30M Series A co-led by RAISE France and Orange Ventures (Sept 2026), opened Boston office (2026), 7 patent applications drafted (2 filed in Europe).

Growth metrics

ARR increased 20x over the last 12 months; more than a dozen enterprise customers in production; headcount doubled to 50 employees over past year, expected to double again; 16x faster systematic literature reviews; 80% efficiency gain in regulatory intelligence/compliance.

Market positioning

Emerging European leader aiming to become the evidence-grade automation layer for regulated life-sciences operations globally; expanding into the US via a Boston office at the heart of the pharma ecosystem.

Geographic focus

Europe (France) primary; expanding to United States (Boston office opened 2026)

Patents and IP

7 patent applications drafted across multiple therapeutic areas; 2 filed in Europe.

About Joël Belafa

Ex-Dataiku (led AI platform engineering, Director of Engineering and AI Field Engineering roles, multi-cloud ML foundations); co-founded Biolevate in 2023.

Latest news about Biolevate

Biolevate Raises €30M Series A for Auditable Life-Sciences AI Workflows

More AI in Healthcare companies

Official website: https://www.biolevate.com/